Talphera Inc. logo

Talphera Inc. (TLPH)

Market Closed
5 Dec, 20:00
NASDAQ (CM) NASDAQ (CM)
$
1. 23
-0.03
-2.38%
$
25.03M Market Cap
- P/E Ratio
0% Div Yield
264,251 Volume
- Eps
$ 1.26
Previous Close
Day Range
1.2 1.29
Year Range
0.38 1.57
Want to track TLPH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

TLPH closed Friday lower at $1.23, a decrease of 2.38% from Thursday's close, completing a monthly decrease of -3.15% or $0.04. Over the past 12 months, TLPH stock gained 132.08%.
TLPH is not paying dividends to its shareholders.
The last earnings report, released on Nov 13, 2025, missed the consensus estimates by -0.01%. On average, the company has surpassed earnings expectations by 0.04%, based on the last three reports.
Talphera Inc. has completed 1 stock splits, with the recent split occurring on Oct 26, 2022.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

TLPH Chart

Similar

Ysxt Tech Co. Ltd.
$ 2.3
-1.29%
MicroCloud Hologram Inc.
$ 3.57
-4.03%
CPS Technologies Corp.
$ 3.29
-2.66%
Quantum BioPharma Ltd.
$ 10.04
+0.4%
Rave Restaurant Group Inc.
$ 2.91
0%
Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript

Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript

Talphera, Inc. ( TLPH ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - CEO & Director Shakil Aslam - Chief Medical Officer Conference Call Participants Nazibur Rahman - Maxim Group LLC, Research Division Presentation Operator Welcome to the Talphera Third Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of Talphera's website at www.Talphera.com.

Seekingalpha | 3 weeks ago
Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript

Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript

Talphera, Inc. (NASDAQ:TLPH ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Raffi Mark Asadorian - Chief Financial Officer Shakil Aslam - Chief Medical Officer Vincent J. Angotti - CEO & Director Conference Call Participants Antonio Eduardo Arce - WestPark Capital, Inc. James Francis Molloy - Alliance Global Partners, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Operator Welcome to the Talphera Second Quarter 2025 Financial Results Conference Call.

Seekingalpha | 3 months ago
Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

Talphera, Inc. (NASDAQ:TLPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Shakil Aslam - Chief Medical Officer Conference Call Participants Operator Welcome to the Talphera First Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of Talphera's website at www.talphera.com.

Seekingalpha | 6 months ago

Talphera Inc. (TLPH) FAQ

What is the stock price today?

The current price is $1.23.

On which exchange is it traded?

Talphera Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is TLPH.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 25.03M.

Has Talphera Inc. ever had a stock split?

Talphera Inc. had 1 splits and the recent split was on Oct 26, 2022.

Talphera Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Vincent J. Angotti CEO
NASDAQ (CM) Exchange
US00444T2096 ISIN
US Country
13 Employees
- Last Dividend
26 Oct 2022 Last Split
- IPO Date

Overview

Talphera, Inc. is a forward-thinking specialty pharmaceutical company with a sharp focus on pioneering and commercializing therapeutic solutions intended for use within medically supervised environments. Initially known as AcelRx Pharmaceuticals, Inc., the organization transitioned to its current identity in January 2024, marking a new chapter in its journey towards innovation in healthcare. Founded in 2005 and with its headquarters nestled in San Mateo, California, Talphera, Inc. is dedicated to addressing a range of medical conditions through its robust pipeline of product candidates.

Products and Services

Niyad: Positioned as Talphera, Inc.'s flagship product candidate, Niyad is a lyophilized formulation of nafamostat. It currently operates under an investigational device exemption, showcasing its promise as a revolutionary anticoagulant specifically designed for use within extracorporeal circuits. This innovation highlights Talphera's commitment to transforming the landscape of medical care in highly specialized settings.

LTX-608: At the cutting edge of Talphera's ambitious project pipeline lies LTX-608. This compound is being explored for its dual anti-inflammatory and antiviral capabilities, with the aim of treating a spectrum of conditions. Among its potential applications are the treatment of COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis, showcasing the vast reach of Talphera's research and development efforts.

Fedsyra: Further expanding its diverse portfolio, Talphera, Inc. introduces Fedsyra, a uniquely pre-filled ephrine syringe designed for precision and ease of use in critical care settings. This development reflects the company’s dedication to addressing the nuanced demands of medical practitioners and patients alike.

PFS-02: Complementing its lineup of innovative healthcare solutions, PFS-02, a pre-filled phenylephrine syringe, stands as a testament to Talphera, Inc.'s commitment to pioneering convenient and reliable options for healthcare providers. This product underscores the company's holistic approach to healthcare innovation, catering to a wide array of medical needs and operational efficiencies.

Contact Information

Address: 1850 Gateway Drive
Phone: 650 216 3500